A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).
Completed · Phase 1
Conditions studied: Head and Neck Squamous Cell Carcinoma
In brief
This biomarker study has been designed to assess the effects of different agents in both tumour tissue and peripheral samples to help inform the best combinations of DDR agents with immuno-oncology (IO) therapies. In the first instance 2 DDR agents will be assessed separately as monotherapy. Additional arms may be added later to evaluate other DDR agents and/or DDR and immunotherapy agents in combination or in sequence. The primary objective of the study is to investigate immune activation due to DDR inhibition by assessing tumour and blood samples of patients treated with study investigational agent(s).
Key facts
- Study ID
- NCT03022409
- Run by
- AstraZeneca
- People needed
- 21
- Starts
- 2017-09-18
- Expected to finish
- 2021-01-20
- Last updated by the study team
- 2021-08-10
Who can join
Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Pittsburgh, Pennsylvania, United States
- Research Site — Toulouse, France
- Research Site — Changhua, Taiwan
- Research Site — Taipei, Taiwan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.